BEIJING, SHANGHAI and BOSTON, May 27, 2022 -- Jacobio Pharma (1167.HK) is pleased to announce that the phase I clinical data of KRAS G12C inhibitor JAB-21822 will be presented in the form of poster at the upcoming 2022 annual meeting of American Society of Clinical Oncology (ASCO) from June 3, 2022 to June 7, 2022. Abstract was published on the ASCO's website today.

"JAB-21822 is one of Jacobio's programs targeting on KRAS pathway, we plan to explore the JAB-21822 in colorectal cancer, pancreatic cancer, and other indications. Meanwhile, Jacobio is exploring combination therapies of JAB-21822, such as in combination with SHP2 inhibitor. We are also developing novel drugs in KRAS pathway, including KRASmulti inhibitor (JAB-23400) and KRAS G12D inhibitor (JAB-22000)," said Dr. WANG Yinxiang, Chairman and CEO of Jacobio.

About the Abstract

A phase I/II study of first-in-human trial of JAB-21822 (KRAS G12C inhibitor) in advanced solid tumors.

Format: Poster Presentation

Abstract Number: 3089

Time: Sunday, June 5, 2022 8:00 AM-11:00 AM (CDT)

Track: Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology

As of January 28, 2022, 53 patients with a median age of 62 years (39-79) were enrolled in 5 different dose levels: 200mg QD, 400mg QD, 800mg QD, 400mg BID and 400mg TID. A total of 33 patients (22 non-small cell lung cancer, 9 colorectal cancer and 2 pancreatic cancer) had at least 1 post-baseline tumor assessment.

• Patients with non-small cell lung cancer (400mg QD and 800mg QD), the overall response rate (ORR) and disease control rate (DCR) were 70% (7/10) and 100% (10/10), respectively.

• No dosing-limiting toxicities were observed. Only Grade 1 and 2 TRAEs were observed in the QD cohorts.

JAB-21822 was well tolerated with impressive preliminary efficacy in patients with heavily treated solid tumors harboring KRAS G12C mutation. The clinical trial is still ongoing and the above data is as of January 28, 2022.

More data will be posted on the poster at the 2022 ASCO Annual Meeting, please visit www.asco.org for more information.

About JAB-21822

JAB-21822 is a KRAS G12C inhibitor independently developed by Jacobio. Jacobio has initiated a number of Phase I/II clinical trials in China, the United States and Europe for patients with advanced solid tumors, including monotherapy for STK11 co-mutated non-small cell lung cancer first-line treatment; combination therapy with SHP2 inhibitor, PD-1 monoclonal antibody and Cetuximab.